Francis M. Cuss - 05 Dec 2025 Form 4 Insider Report for Mural Oncology plc (MURA)

Reporting relationship: Director
Issuer ticker: MURA
Reported as of: 05 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Dec 2025, 09:04:18 UTC
Prior SEC filing: 13 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Francis M. Cuss

Key filing fact

Francis M. Cuss filed Form 4 for Mural Oncology plc (MURA) on 05 Dec 2025.

Key facts

This page summarizes Francis M. Cuss's Form 4 filing for Mural Oncology plc (MURA).
3 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 05 Dec 2025, 09:04.

Change

Previous filing in this sequence was filed on 13 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001490216 Primary reporting owner

Cuss Francis M

Relationship: Director
Address: C/O MURAL ONCOLOGY PLC, 10 EARLSFORT TERRACE, DUBLIN 2, IRELAND
Signature: /s/ Francis M. Cuss
Signature date: 05 Dec 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MURA transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -8,637
Change %: -100%
Price
Shares after: 0
Date: 05 Dec 2025
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 8,637
Exercise price: $2.56
Footnotes: F1, F2

MURA transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -8,462
Change %: -100%
Price
Shares after: 0
Date: 05 Dec 2025
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 8,462
Exercise price: $3.35
Footnotes: F2

MURA transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -15,021
Change %: -100%
Price
Shares after: 0
Date: 05 Dec 2025
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 15,021
Exercise price: $3.61
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Francis M. Cuss is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

This Form 4 reports securities disposed of pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, pursuant to which Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"). The Acquisition was completed as of December 5, 2025 (the "Effective Time").

Footnote F2

Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options.